Switch theme
Sign up to access all valuation multiples
SenzaGen AB markets sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its laboratory and licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe.
2010
34
LTM Revenue $6.4M
LTM EBITDA -$0.3M
$12.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SenzaGen has a last 12-month revenue (LTM) of $6.4M and a last 12-month EBITDA of -$0.3M.
In the most recent fiscal year, SenzaGen achieved revenue of $6.0M and an EBITDA of -$0.8M.
SenzaGen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SenzaGen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.4M | XXX | $6.0M | XXX | XXX | XXX |
| Gross Profit | $6.4M | XXX | $4.0M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | -$0.3M | XXX | -$0.8M | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | -13% | XXX | XXX | XXX |
| EBIT | -$1.4M | XXX | -$1.1M | XXX | XXX | XXX |
| EBIT Margin | -22% | XXX | -18% | XXX | XXX | XXX |
| Net Profit | -$1.3M | XXX | -$1.8M | XXX | XXX | XXX |
| Net Margin | -21% | XXX | -31% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, SenzaGen's stock price is SEK 5 (or $1).
SenzaGen has current market cap of SEK 154M (or $15.9M), and EV of SEK 121M (or $12.5M).
See SenzaGen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.5M | $15.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, SenzaGen has market cap of $15.9M and EV of $12.5M.
SenzaGen's trades at 2.1x EV/Revenue multiple, and -16.1x EV/EBITDA.
Equity research analysts estimate SenzaGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SenzaGen has a P/E ratio of -11.8x.
See valuation multiples for SenzaGen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15.9M | XXX | $15.9M | XXX | XXX | XXX |
| EV (current) | $12.5M | XXX | $12.5M | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | -44.7x | XXX | -16.1x | XXX | XXX | XXX |
| EV/EBIT | -8.9x | XXX | -11.4x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.8x | XXX | -8.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -8.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSenzaGen's last 12 month revenue growth is 27%
SenzaGen's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
SenzaGen's rule of 40 is 6% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SenzaGen's rule of X is 63% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SenzaGen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 27% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | -13% | XXX | XXX | XXX |
| EBITDA Growth | -265% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 6% | XXX | 14% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 85% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SenzaGen acquired XXX companies to date.
Last acquisition by SenzaGen was XXXXXXXX, XXXXX XXXXX XXXXXX . SenzaGen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SenzaGen founded? | SenzaGen was founded in 2010. |
| Where is SenzaGen headquartered? | SenzaGen is headquartered in Sweden. |
| How many employees does SenzaGen have? | As of today, SenzaGen has 34 employees. |
| Is SenzaGen publicy listed? | Yes, SenzaGen is a public company listed on STO. |
| What is the stock symbol of SenzaGen? | SenzaGen trades under SENZA ticker. |
| When did SenzaGen go public? | SenzaGen went public in 2017. |
| Who are competitors of SenzaGen? | Similar companies to SenzaGen include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of SenzaGen? | SenzaGen's current market cap is $15.9M |
| What is the current revenue of SenzaGen? | SenzaGen's last 12 months revenue is $6.4M. |
| What is the current revenue growth of SenzaGen? | SenzaGen revenue growth (NTM/LTM) is 27%. |
| What is the current EV/Revenue multiple of SenzaGen? | Current revenue multiple of SenzaGen is 1.9x. |
| Is SenzaGen profitable? | Yes, SenzaGen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SenzaGen? | SenzaGen's last 12 months EBITDA is -$0.3M. |
| What is SenzaGen's EBITDA margin? | SenzaGen's last 12 months EBITDA margin is -4%. |
| What is the current EV/EBITDA multiple of SenzaGen? | Current EBITDA multiple of SenzaGen is -44.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
